You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 41 No. 6, June 1984 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (50)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Tardive Dyskinesia

A Discontinuation Study

William M. Glazer, MD; Daniel C. Moore, MD; Nina R. Schooler, PhD; Louise M. Brenner, RN; Hal Morgenstern, PhD

Arch Gen Psychiatry. 1984;41(6):623-627.


Abstract

• Twenty-one nonschizophrenic and 12 schizophrenic outpatients with tardive dyskinesia (TD) were followed up for a mean of 12.0 and 8.6 months, respectively, following discontinuation of neuroleptic therapy. Of the 33 patients, only one demonstrated complete reversal of TD. Cumulative survival curves of the length of time to first improvement (reduction in movement ratings by 50% of baseline) did not differ between the two groups. The median time to first improvement was seven months. If a patient can be kept off of a neuroleptic regimen for 18 months, the estimated probability of showing a 50% reduction in movement is 87.2%. In the nonschizophrenic group, depressed mood was negatively correlated with severity of abnormal movements.



Author Affiliations

From the Departments of Psychiatry (Drs Glazer and Moore) and Epidemiology and Public Health (Dr Morgenstern), Yale University School of Medicine, New Haven; the Connecticut Mental Health Center, New Haven (Ms Brenner); and the Pharmacology and Somatic Treatments Research Branch, National Institute of Mental Health, Bethesda, Md (Dr Schooler).


Footnotes

Accepted for publication Sept 22, 1983.

Read before the 135th Annual Meeting of the American Psychiatric Association, Toronto, May 19, 1982.

Reprint requests to 34 Park St, New Haven, CT 06519 (Dr Glazer).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Risperidone for tardive dyskinesia.
CHEN et al.
Am. J. Psychiatry 2001;158:1931-1932.
FULL TEXT  

Tardive Dyskinesia in Young Mentally Retarded Individuals
Gualtieri et al.
Arch Gen Psychiatry 1986;43:335-340.
ABSTRACT  

Penrsistent Tardive Dyskinesia in Bipolar Patients
Mukherjee et al.
Arch Gen Psychiatry 1986;43:342-346.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1984 American Medical Association. All Rights Reserved.